

Nanexa signs evaluation agreement with a Speciality Pharma company

Nanexa AB (publ) today announced that the company has signed a Material Transfer and Feasibility Study Agreement with a Speciality Pharma company, for evaluation of the PharmaShell® drug delivery system making a depot formulation of specific compounds for intravitreal delivery.

This feasibility study is directed towards a specific commercial drug product using the PharmaShell technology with the intention to make long-acting injectable products for intravitreal delivery.

"A very interesting approach in this evaluation using our PharmaShell system for intravitreal delivery, where the high drug load we can accomplish is a true key benefit. Having a local and targeted release of the active compound in the eye could potentially give multiple benefits. It is also very exciting for Nanexa to enter into the collaboration with this speciality pharma company and we look forward to starting the work shortly with the aim to generate results that can provide basis for a more extensive development program and a long-term license agreement", said David Westberg, CEO of Nanexa.

The agreement regulates, among other things, details of what shall be investigated, clarification regarding patent rights, and a determined fee to Nanexa for this evaluation.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Press Release
21 October 2022 10:00:00 CEST



Attachments

[Nanexa signs evaluation agreement with a Speciality Pharma company](#)